Diabetic nephropathy is a serious microvascular complication of both type 1 and type 2 diabetes, associated with endstage renal failure (ESRF) and premature death from cardiovascular disease 1 . Signs of the nephropathy may be detected after only ®ve years of hyperglycaemia. Macroalbuminuria is the hallmark of the condition (albumin excretion rate [AER] 4200 mg min 71 or 4300 mg 24 h 71 ), but this is preceded by a phase of microalbuminuria (AER 20±200 mg min 71 or 30±300 mg 24 h 71 ). Antihypertensive therapy at this stage, even in normotensive individuals, may slow the progression to ESRF 2 . Possibly as a result of improvements in glycaemic control and blood pressure therapy, the incidence of diabetic nephropathy seems to be declining and the prognosis is improving 3 . In this paper, we review the evidence for a role of genetic factors in nephropathy, and the genes postulated as having a role in the pathogenesis of the condition.
WHY GENES FOR DIABETIC NEPHROPATHY?
Hyperglycaemia is not suf®cient Several factors seem to be implicated in the genesis of diabetic nephropathy. Whilst the Diabetes Control and Complications Trial (DCCT) showed that tight control of hyperglycaemia can reduce the incidence of nephropathy it is clear that hyperglycaemia alone is not suf®cient for development of the condition. Long-term observational studies show that a maximum of 35% of patients develop nephropathy, irrespective of glycaemic control 4, 5 . This contrasts sharply with diabetic retinopathy, where prevalence increases linearly with duration of diabetes 6 . This implies that a subgroup of patients with type 1 diabetes are at high risk of nephropathy, possibly because of hereditary factors.
Nephropathy occurs in families
The strongest evidence for genetic factors in nephropathy comes from studies of families with type 1 diabetes. Early work in Sweden and the USA showed that, in families with two or more type 1 diabetic siblings, when one sibling developed nephropathy, the other was at fourfold risk of nephropathy compared with a sibling of a patient without nephropathy 7, 8 . This ®nding has been reproduced in a much larger analysis where, if the proband had nephropathy, the cumulative risk of nephropathy to diabetic siblings was 71.5%. This risk fell to 25.4% where the proband did not have nephropathy 9 . Examination of the DCCT cohort has revealed similar ®ndings 10 .
Family history of hypertension or cardiovascular disease predisposes to nephropathy
Parents of patients with type 1 diabetes who develop nephropathy have higher arterial blood pressures (15/ 8 mmHg greater) than parents of patients who have no nephropathy 11±13 . Data from the EURODIAB type 1 diabetes complications study have also shown that the mean age-adjusted blood pressure is signi®cantly higher in those patients reporting parental hypertension 14 . Similarly, parents of type 1 diabetic patients with nephropathy seem to have more cardiovascular disease than parents of type 1 diabetic patients with normal albumin excretion 15 . Furthermore, parents of proteinuric type 1 diabetic patients die at an earlier age, have higher arterial blood pressure, and have more hyperlipidaemia and insulin resistance than parents of normoalbuminuric patients 16 .
Recently there has been speculation that albuminuria, cardiovascular disease and hypertension may be linked by an inherited predisposition to insulin resistance. Patients with nephropathy are more insulin-resistant than nonnephropathic patients 17, 18 . Increased insulin resistance has also been noted in parents of type 1 diabetic patients with proteinuria 19 .
WHY LOOK FOR A GENETIC MARKER?
The search for genetic markers of increased risk of diabetic nephropathy is important for several reasons. First, it will de®ne a group of people with type 1 diabetes who are predisposed to nephropathy at the time of diagnosis; this group could then be offered careful follow-up and possibly early therapeutic intervention. Second, by establishing the identity and function of the genetic marker(s), we might gain insights into the pathogenesis of the condition and so devise new therapeutic approaches.
METHODS OF GENETIC DISSECTION

Linkage analysis in families
In broad terms, there are two strategies for identifying susceptibility genes for diabetic nephropathyÐlinkage analysis and population association (case±control) studies. Linkage analysis by use of affected pedigrees is generally preferred to case±control studies but there are dif®culties in establishing such a resource for diabetic nephropathy. The complex inheritance of type 1 diabetes means that large multigeneration pedigrees are generally unavailable for study. Analysis of affected sibling pairs (ASPs) (successfully used to examine genetic susceptibility to type 1 diabetes) is an alternative strategy but suitable families are rare. The concurrent analysis of discordant sib-pairs would accelerate such a collection but the stringent criteria required to prove discordance imply that these sibships will likewise be uncommon.
Case±control (association) studies
Association studies involve the comparison of allele and genotype frequencies at genetic loci (usually candidate genes) in individuals with the condition of interest and in controls. For diabetic nephropathy, collection of large numbers of cases is problematic in view of the high attrition rate of this complication, and, for this reason, multicentre collections are required. Large cohorts of individuals with diabetic nephropathy have now been established within the UK and elsewhere, generating numerous statistically signi®cant associations. However, despite best efforts to match cases and controls in association analysis, there remains the possibility that signi®cant associations are due to hidden population strati®cation and are spurious. Additional analyses are therefore required to con®rm positive ®ndings.
Association studies within families
Family-based association analysis is currently regarded as the gold-standard test of a genetic association. The transmission/ disequilibrium test (TDT) is commonly used and this involves analysis of the frequency of transmission of designated alleles from heterozygous parents to affected offspring 20 . Information on parental genotype is therefore mandatory, though when both parents are unavailable this can be inferred (with appropriate statistical correction) from sibling genotypes. In contrast, the phenotype of the parents is immaterial for this analysis and so there is no requirement that they be diabetic patients with nephropathy (indeed most of the parents will be non-diabetic). The ®nding of allelic association not only con®rms a population association but also places the susceptibility locus to within a region of approximately 2 megabases. Chromosome regions of this size are small enough to allow physical mapping and, potentially, the identi®cation of causal polymorphisms and speci®c gene mutations.
CANDIDATE GENE CASE±CONTROL STUDIES IN DIABETIC NEPHROPATHY
Human leucocyte antigen and insulin genes
The major histocompatibility complex (MHC) on chromosome 6 encodes human leucocyte antigens (HLA) which contribute to susceptibility to type 1 diabetes. These genes have also been postulated to have a role in susceptibility to microvascular disease 21 . Twin studies of type 1 diabetes show concordance for retinopathy status, especially those twins with the DR3/4 genotype 22 . However, in our own association studies of HLA loci in large cohorts of type 1 diabetic patients with and without nephropathy (n=675) we have found no positive or negative associations with HLA markers 23 .
The insulin (INS) gene region is also a susceptibility locus for diabetes (IDDM2). This gene has been implicated in premature atherosclerosis and has thus been examined as a candidate for diabetic nephropathy; once again the results are negative 23 .
Renin±angiotensin system genes
Angiotensin-converting enzyme
Elevations in prorenin, renin, angiotensin-converting enzyme (ACE) and angiotensin II levels are observed in diabetic nephropathy 24 . Genes encoding components of the renin±angiotensin system have been suggested as susceptibility determinants for hypertension and cardiovascular disease, both of which are common in patients with diabetic nephropathy.
The gene encoding ACE has a polymorphism characterized by insertion (I) or deletion (D) of a 256 base-pair segment of DNA 25 . Each person carries two copies of the gene, and II genotype carriers have low levels of serum ACE whilst DD carriers have high levels (ID carriers are intermediate). Individuals with the DD genotype may have a higher risk of coronary artery disease than those with other genotypes. In nephropathy, small studies have also suggested a positive association with the D allele 26,27 but these observations have not been con®rmed 28±30 and one study has suggested that the association is, in fact, between nephropathy and the I allele. This rather confusing situation cannot be clari®ed by resort to meta-analysis since the bias towards publication of`positive' studies is especially strong in the genetics ®eld.
The ACE D allele may, however, have a role in the natural history of diabetic nephropathy. A small group of patients with the II genotype were found to have a 51.3% reduction in AER after 2 years of lisinopril therapy compared with a 14.8% reduction in the ID group and a
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V o l u m e 9 3 F e b r u a r y 2 0 0 0 7.7% reduction in the DD group 31, 32 . This trend towards reduced renoprotection with ACE inhibitors according to ACE genotype has also been observed in non-diabetic renal failure 33 .
Angiotensinogen
The angiotensinogen gene has a diallelic M235T polymorphism and the T allele of this has been associated with hypertension and coronary artery disease 34 . This polymorphism has therefore been examined in cohorts with diabetic nephropathy. As with ACE, a small early study suggested a weak association of the TT genotype with nephropathy 35 , but subsequent larger studies found no association 30, 36, 37 .
Angiotensin II type 1 receptor gene
The C allele of the A1166C polymorphism of the angiotensin II type 1 receptor gene has also been linked to essential hypertension 38 , and hence has been examined in diabetic nephropathy. Two large studies have now suggested no role for this polymorphism in diabetic nephropathy 39, 40 .
Aldose reductase
This enzyme is important in the polyol pathway, and is suggested as contributing to diabetic microangiopathic complications. Polymorphism of this gene has been reported to be strongly associated with nephropathy in type 1 diabetes 41 but the ®nding is based on small numbers and has not been replicated in our own larger cohorts 42 or by other groups 43 . It is noteworthy that the aldose reductase gene lies in a region of putative linkage to diabetic nephropathy in two study cohorts (Pima Indians and North American whites). However, polymorphism within the gene itself was not associated with nephropathy in either population, so it is very unlikely to have a role in the complication.
Heparan sulphate
According to the`Steno hypothesis', heparan sulphate from the glomerular basement membrane may be a major pathogenic factor in diabetic nephropathy 44 . Our own large study has shown a signi®cant association of a heparan sulphate core protein (HSPG2) gene polymorphism with nephropathy 45 . This con®rmed a report in a large cohort of Danish diabetic patients. Whether the ®nding is replicable in other populations remains to be seen.
Apolipoprotein E
Apolipoprotein E (ApoE) is a protein constituent of lipoproteins, and is of major importance in lipid metabolism. Subtle variation of ApoE can result in great changes in lipid pro®le, leading to increased atherogenicity. The ApoE gene polymorphism is triallelic (three variants), of which the E2 allele may have a role in susceptibility to nephropathy 46 . Once again, this result has yet to be replicated.
DIFFICULTIES WITH CURRENT STUDIES
As illustrated above, case±control studies can give very divergent results. Inadequate numbers of cases and controls can give rise to false-positive or false-negative results. Inadequate phenotyping (i.e. inclusion of proteinuric diabetics who do not have nephropathy) may also contribute to the divergence. Other confounding factors include population admixture (mixture of various races analysed together), population strati®cation (unrecognized differences between cases and controls), multiple hypothesis testing, subgroup analysis and publication bias (preference for positive results). Overall this tends to lead to an initial surge of positive ®ndings which fail the test of replication.
THE WAY FORWARD
Clearly the dissection of the genetics of diabetic nephropathy is far from easy. The methodology so far used has several¯aws, and whilst some clues as to the role of some genes in nephropathy may have been gleaned, no signi®cant genetic marker has been found. The search for such a genetic marker will require a different approach. The most powerful method available, attainable in an appropriate time-span, is the use of association studies within families by means of the transmission/disequilibrium test. This involves analysis of the frequency of transmission of designated alleles from heterozygous parents to affected offspring 20 . This method has the advantages of requiring smaller numbers than ASP analysis, and also requires DNA only from parents and the affected patients (so-called trios). This methodology is being used in a large-scale collection of families from the UK sponsored by the British Diabetic Association. Replication of any results obtained from this cohort is clearly necessary, so a similar collection in the USA (to be sponsored by the Juvenile Diabetes Foundation) is a welcome development.
CONCLUSIONS
Incidence studies, family studies and parental history studies suggest that genetic factors are important in the pathogenesis of diabetic nephropathy. Numerous case± control studies have been reported, often with con¯icting results. More recent family linkage studies are still hampered by small numbers. Collection of a large number of affected patients and their parents is an attainable goal, and may prove to be the principal way forward in the dissection of the genetics of diabetic nephropathy. 
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